FindTrial
Sign In

EGFR/EGFRvIII Inhibitor WSD0922-FU

DRUG2 trials

Sponsors

Mayo Clinic

Conditions

Anaplastic Astrocytoma, IDH-WildtypeGlioblastoma, IDH-WildtypeMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the Central Nervous SystemStage IV Lung Cancer AJCC v8

Phase 1

WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Active, not recruitingNCT04197934
Mayo ClinicAnaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma +2
Start: 2019-12-20End: 2031-02-06Updated: 2026-08-10

Phase 2

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
RecruitingNCT07708961
Mayo ClinicGlioblastoma, IDH-Wildtype
Start: 2026-08-28End: 2036-08-31Target: 60Updated: 2026-09-02

Related Papers

CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology2025-11-01
A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).
Journal of Clinical Oncology2025-05-28
CTNI-03. EFFICACY OF WSD0922-FU IN OSIMERTINIB-RESISTANT NSCLC WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES – UPDATES FROM THE DOSE ESCALATION COHORT OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
Neuro-Oncology2023-11-011 citations
TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS
Neuro-Oncology Advances2023-08-01
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.
Journal of Clinical Oncology2023-06-014 citations